An FDA panel has voted unanimously to withdraw approval for Roche?s Avastin for use in the treatment of metastatic breast cancer because there is not enough data to support the conclusion that the benefits outweigh the risks. The fate of Avastin in this indication now lies in the hands of FDA Commissioner Margaret Hamburg, who will make the final decision after the period for public comments closes at the end of July. Roche will also have the opportunity to submit its final summary on the matter.
An FDA panel has voted unanimously to withdraw approval for Roche’s Avastin for use in the treatment of metastatic breast cancer because there is not enough data to support the conclusion that the benefits outweigh the risks. The fate of Avastin in this indication now lies in the hands of FDA Commissioner Margaret Hamburg, who will make the final decision after the period for public comments closes at the end of July. Roche will also have the opportunity to submit its final summary on the matter.
“We are very disappointed by the committee’s recommendation and hope the Commissioner does not decide to remove this important medicine for women with an incurable disease who already have too few treatment options,” said Hal Barron, chief medical officer and head of global product development at Roche, in a statement. “We remain ready to collaborate with FDA to find a solution that is in the best interest of patients who need Avastin.” Despite the proceedings, the US Centers for Medicare and Medicaid Services (CMS) have reportedly said that Medicare will continue to pay for Avastin.
“The FDA decision, when it comes, does not affect CMS,” Don McLeod, a spokesman for CMS, told Reuters. “The drug will still be on the market, doctors will still be prescribing it, and we will continue to pay for it.”
Whatever FDA decides, Roche’s statement added that the proceedings will have no impact on Avastin’s approved uses for other cancer types in the US, or the use of Avastin for metastatic breast cancer in other countries.
Both FDA and the European Medicines Agency (EMA) scrutinized the risk–benefit profile of Avastin in 2010. In December 2010, EMA concluded that Avastin in combination with paclitaxel remained a “valuable” treatment option for women with breast cancer, but not with other combinations.
Last week, Avastin also received a broader European Union label that enables the drug to be used in combination with Roche’s Xeloda as a first-line treatment when other chemotherapies are not considered appropriate.
FDA, on the other hand, had a different opinion on the matter. In December 2010, FDA recommended that the breast cancer indication be removed from the Avastin label because the drug had not been shown to be “safe and effective for that use.” Roche appealed the ruling and refused FDA’s recommendation to voluntarily withdraw Avastin’s breast cancer indication—the first company to ever do so, according to a report from EP Vantage.
The deadline for public comments is July 28, 2011. The final decision will be made after this date.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Top 10 Cleanroom Problems That Can Be Prevented via Preventative Maintenance (May 2025)
May 16th 2025Cleanrooms require strict environmental control to maintain sterility, prevent contamination, and ensure seamless operations. Without a proactive preventative maintenance (PM) program, various issues can arise, leading to costly downtime, contamination risks, and operational inefficiencies. Below are ten common cleanroom problems that can be effectively mitigated through proper PM practices.